The analysts wrote, “Apricus offers a niche men’s sexual health product and a pipeline program in female sexual health: Vitaros is a topical cream that has been recently approved for the treatment of erectile dysfunction (ED) in Europe. We expect peak royalties of $35M based on revenues of ~$300M along with $15M in transfer pricing. A second topical cream for the treatment of female sexual dysfunction (Femprox) still has to progress through late-stage clinical trials. We need to get comfortable with the development pathway for this asset but think that positive data in the 2016 time frame could make Apricus significantly more attractive. Because we think the story needs more time to develop, we are taking a cautious stance on the stock and initiating coverage with a HOLD rating and $2.00 price target (PT
Everybody on this board knows we have 98 mil in upfront payments due, plus royalties . This person has done no homework and in my opinion, doesn't have a clue. How could the price target be $2 when the stock is higher now? Bad info or a misprint. OR just totally misinformed, must be one of Cramers people.
" NINETY-EIGHT MIL ", huh, 'bob' !??? ..... what did you do - move to Colorado to smoke that "legatized" stuff !??? LOL.....hahahahahahahahahaha ! WHERE does it say that APRI is EVER gonna get that kinda $$$$$, and, "UP FRONT" , no less !??? WHERE !?!??